
Results
9
Stocks with a return on equity of over 30% and a debt to equity ratio below 1.
9 companies
Johnson & Johnson
Market Cap: US$494.7b
Engages in the research and development, manufacture, and sale of various products in the healthcare field worldwide.
JNJ
US$202.48
7D
-2.4%
1Y
35.4%
Merck
Market Cap: US$253.8b
Operates as a healthcare company worldwide.
MRK
US$100.89
7D
-3.6%
1Y
-2.6%
Exelixis
Market Cap: US$11.9b
An oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States.
EXEL
US$44.37
7D
0.5%
1Y
23.9%
ADMA Biologics
Market Cap: US$4.8b
A biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally.
ADMA
US$20.11
7D
4.8%
1Y
1.5%
CorMedix
Market Cap: US$838.3m
A biopharmaceutical company, focuses on developing and commercializing therapeutic products for life-threatening diseases and conditions in the United States.
CRMD
US$10.64
7D
8.5%
1Y
12.0%
SIGA Technologies
Market Cap: US$454.0m
A commercial-stage pharmaceutical company, focuses on the health security market in the United States.
SIGA
US$6.34
7D
4.6%
1Y
-8.9%
Puma Biotechnology
Market Cap: US$261.5m
A biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally.
PBYI
US$5.29
7D
4.8%
1Y
72.3%
Abeona Therapeutics
Market Cap: US$256.3m
A clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases.
ABEO
US$4.87
7D
-5.4%
1Y
-19.0%
BioStem Technologies
Market Cap: US$72.8m
A life sciences corporation, focuses on discovering, developing, and producing pharmaceutical and regenerative medicine products and services.
BSEM
US$4.28
7D
-11.4%
1Y
-68.7%